Emmaus Life Sciences, INC. (EMMA) — 10-Q Filings

10-Q Filings (5)

• Emmaus Life Sciences' Revenue Plummets 35% Amid Mounting Losses — Nov 14, 2025 Risk: high
  Emmaus Life Sciences, Inc. (EMMA) reported a significant decline in net revenues for the nine months ended September 30, 2025, falling to $8.601 million from $1
• Emmaus Revenues Plunge, Going Concern Doubts Persist Amidst Debt Load — Aug 14, 2025 Risk: high
  Emmaus Life Sciences, Inc. (EMMA) reported a significant decline in net revenues for the three and six months ended June 30, 2025. Net revenues decreased by 47.
• Emmaus Life Sciences Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Emmaus Life Sciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial
• Emmaus Life Sciences Files Q3 2024 10-Q — Nov 19, 2024 Risk: medium
  Emmaus Life Sciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as MYnd Analytics, Inc., reported on its financi
• Emmaus Life Sciences 10-Q: Financials and Derivatives — Sep 10, 2024 Risk: medium
  Emmaus Life Sciences, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported a net loss on investment in a convertible bond and a gain/l

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX